Acadia Pharmaceuticals traded at $15.12 this Wednesday July 6th, decreasing $0.15 or 0.98 percent since the previous trading session. Looking back, over the last four weeks, Acadia Pharmaceuticals lost 17.24 percent. Over the last 12 months, its price fell by 36.92 percent. Looking ahead, we forecast Acadia Pharmaceuticals to be priced at 13.98 by the end of this quarter and at 12.87 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Eisai 6,174.00 7.00 0.11% -41.17%
Acadia Pharmaceuticals 15.12 -0.15 -0.98% -36.92%
ALKERMES 31.87 0.44 1.40% 25.03%
Alnylam Pharmaceuticals 150.00 -0.73 -0.48% -13.09%
Aptinyx Inc 0.57 0.04 7.51% -79.04%
Biogen 215.98 3.40 1.60% -39.22%
BioMarin Pharmaceutical 86.41 0.05 0.06% 4.06%
Bristol-Myers Squibb 76.22 0.26 0.34% 13.52%
Cara Therapeutics 9.59 0.37 4.01% -30.76%
Corcept Therapeutics 26.21 0.48 1.87% 17.27%
Cytokinetics 44.14 0.24 0.55% 123.27%
Intercept Pharmaceuticals 15.29 0.14 0.92% -19.44%
Incyte Corp 79.72 0.47 0.59% -2.93%
Intra Cellular Therapies 56.17 -0.92 -1.61% 37.00%
J&J 178.30 0.16 0.09% 5.25%
Eli Lilly 330.15 2.97 0.91% 40.00%
Moderna Inc 159.56 4.02 2.58% -28.09%
Marinus Pharmaceuticals 4.77 -0.25 -4.98% -74.56%
Neurocrine Biosciences 95.20 -3.10 -3.15% -3.05%
Pfizer 52.75 1.11 2.15% 34.05%
Prothena 29.60 -0.09 -0.30% -44.42%
PTC Therapeutics 42.91 -0.87 -1.99% -2.57%
Ultragenyx Pharmaceutical 63.38 -0.42 -0.66% -29.29%
Seattle Genetics 175.13 -1.64 -0.93% 16.96%
Sarepta Therapeutics 75.97 0.23 0.30% 5.53%
Vanda Pharmaceuticals 11.69 0.19 1.65% -42.10%
Vertex Pharmaceuticals 291.16 2.18 0.75% 46.32%

Indexes Price Day Year
USND 11362 39.61 0.35% -22.52%
US2000 1728 -13.78 -0.79% -23.32%

Acadia Pharmaceuticals
Acadia Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of medicines to address unmet medical needs in central nervous system disorders. The Company's product pipeline includes NUPLAZID (pimavanser), Trofinetide, ACP-044 and ACP-319. NUPLAZID (pimavanserin) is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). NUPLAZID is a selective serotonin inverse agonist/antagonist, preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors. Trofinetide is a synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome. ACP-044, is an orally administered, non-opioid analgesic being evaluated for the treatment of pain. ACP-319 is a positive allosteric modulator of the muscarinic receptor targeting M1 (M1 PAM).